Evidence map›Paper›PMID 28486551›Full record

ArticlePloS one2017

Survival comparison between radical surgery and definitive chemoradiation in 267 esophageal squamous cell carcinomas in a single institution: A propensity-matched study.

Hideomi Yamashita, Yasuyuki Seto, Ryousuke Takenaka, Kae Okuma, Tomoki Kiritooshi, Kazuhiko Mori, Kazuhiko Yamada, Takashi Fukuda, Michio Kaminishi, Osamu Abe and 1 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.Esophagus : official journal of the Japan Esophageal Society · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The British journal of radiology · 2018
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Hideomi YamashitaDepartment of Radiology, University of Tokyo Hospital, Tokyo, Japan.ORCID http://orcid.org/0000-0001-9394-9490
Yasuyuki SetoDepartment of Gastrointestinal Surgery, University of Tokyo Hospital, Tokyo, Japan.
Ryousuke TakenakaDepartment of Radiology, University of Tokyo Hospital, Tokyo, Japan.
Kae OkumaDepartment of Radiology, University of Tokyo Hospital, Tokyo, Japan.
Tomoki KiritooshiDepartment of Radiology, University of Tokyo Hospital, Tokyo, Japan.
Kazuhiko MoriDepartment of Gastrointestinal Surgery, Mitui Memorial Hospital, Tokyo, Japan.
Kazuhiko YamadaDepartment of Gastrointestinal Surgery, National Center for Global Health and Medicine, Tokyo, Japan.
Takashi FukudaDepartment of Gastrointestinal Surgery, Saitama Cancer Center, Saitama, Japan.
Michio KaminishiDepartment of Gastrointestinal Surgery, Showa General Hospital, Tokyo, Japan.
Osamu AbeDepartment of Radiology, University of Tokyo Hospital, Tokyo, Japan.
Keiichi NakagawaDepartment of Radiology, University of Tokyo Hospital, Tokyo, Japan.
University of Tokyo Hospital · JPMitsui Memorial Hospital · JPNational Center for Global Health and Medicine · JPSaitama Cancer Center · JPShowa General Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo compare radical surgery with definitive chemoradiation (CRT) for esophageal squamous cell carcinoma using propensity score (PS) matching at our single institution. MATERIALS AND

methodsA total of 386 consecutive, surgically treated and 243 CRT-treated cases between 2001 and 2014 were analyzed. PS was calculated using multivariable analysis (logistic regression) for pairs of variables such as treatment time, age, sex, primary tumor location, clinical stage, and clinical T- and N-stage for patients after excluding clinical T4 and M1 cases. According to PS, 133 surgically-treated and 134 CRT-treated cases were selected randomly by software.

resultsThe patients' median age was 68 years in the CRT group and 71 years in the surgery group. Clinical stage II-III, T3, N0 (according to the 7th American Joint Committee on Cancer-2009), and upper plus middle thoracic esophageal disease were seen in 68%, 44%, 54%, and 59%, respectively, in the CRT group and 64%, 47%, 55%, and 64%, respectively, in the surgery group. The 3- and 5-year overall survival was 47.1% and 34.0% in the CRT group and 68.3% and 54.4% in the surgery group (p = 0.0019). The 3- and 5-year progression-free survival was 45.3% and 38.8% in the CRT group and 61.1% and 54.4% in the surgery group (p = 0.022).

conclusionCRT may be inferior to surgery in survival, although a selection bias for patients selected for a non-operative approach cannot be excluded, especially since surgery is the standard of care at this institution. A prospective randomized clinical trial will be necessary to draw a definite conclusion.

Indexed as

Survival AnalysisAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Squamous CellChemoradiotherapyCisplatinEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleFluorouracilHumansMaleMiddle AgedCisplatinFluorouracil

Identifiers

PMID28486551
PMCPMC5423615
OpenAlexW2612660742

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.